APA (7th ed.) Citation

Alexander Egeberg, Denis Jullien, Kristian Gaarn Du Jardin, & Diamant Thaçi. (2023). Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): Number needed to harm for occurrence of adverse events of special interest. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Alexander Egeberg, Denis Jullien, Kristian Gaarn Du Jardin, and Diamant Thaçi. Five-year Safety of Tildrakizumab in Patients with Moderate-to-severe Psoriasis from Two Phase 3 Trials (reSURFACE 1 and ReSURFACE 2): Number Needed to Harm for Occurrence of Adverse Events of Special Interest. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Alexander Egeberg, et al. Five-year Safety of Tildrakizumab in Patients with Moderate-to-severe Psoriasis from Two Phase 3 Trials (reSURFACE 1 and ReSURFACE 2): Number Needed to Harm for Occurrence of Adverse Events of Special Interest. Taylor & Francis Group, 2023.